P
ProHub
English 简体中文 繁體中文
BCG Medium Profitability

DrugCo

#Healthcare

Practice this intermediate profitability case interview question from BCG in the Healthcare sector. Includes detailed problem prompt, clarifying questions, structured framework, and expert recommendation. Part of ProHub's 835+ consulting case library.

ProHub Comment

This is an interviewee-led case that requires diagnostic thinking to identify that the client has inverted approval rates compared to industry peers. The root cause is lax early-stage approval standards leading to more expensive later-stage testing, increasing per-drug costs despite launching the same number of products. The candidate must synthesize this insight and generate creative solutions around operational improvements.

Estimated Time 25 minutes
Difficulty Medium
Source Cornell
52 / 100
Our client is pharmaceutical drug company. The company is less profitable on approved drugs than its peer companies. The client has engaged our team to diagnose the issue and provide a recommendation.

Clarifying Information

  1. Both the client and peer companies (the industry) have the same number of drugs before pre-clinical trial (e.g. 100 drugs).
  2. After testing and approving, the client and the industry launch the same number of drugs.
  3. 100 → 5.4
  4. No material differences between drugs from the client and the industry
Mock Interview
Interviewer

Our client is pharmaceutical drug company. The company is less profitable on approved drugs than its peer companies. The client has engaged our team to diagnose the issue and provide a recommendation.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

DrugCo is less profitable than competitors despite launching the same number of approved drugs. Analysis reveals the client approves more drugs in early phases (Pre-Clinical through Phase 2) than the industry, but these later fail in Phase 3. This creates higher aggregate R&D costs per approved drug. The solution requires implementing stricter early-stage approval criteria.

Key Insights:

  1. Approval rates are inverted: client has higher approval rates in Pre-Clinical/Phase 1/Phase 2, but lower in Phase 3 compared to industry
  2. The cost structure problem: later development phases are exponentially more expensive to test, so allowing more drugs to advance to Phase 2-3 increases total R&D spend despite same final launch volume
  3. Root cause is operational: lax approval standards in early phases rather than drug quality differences
  4. Solutions span multiple levers: financial incentives, management pressure, equipment upgrades, and employee expertise development

Practice More Case Interview Questions

Browse 835+ real consulting case interview examples from top firms. Filter by difficulty, company, industry, or case type. Or try our AI mock interview for instant feedback and scoring.

Browse All Cases How to Practice Case Interviews